TEVAR in patients with connective tissue diseases is feasible but still questionable regarding their young age and the rates of endoleaks and reintervention due to disease progression. Close surveillance is mandatory. Low morbidity and mortality rates may justify TEVAR in emergencies as a "bridging" method.
No takes yet. Share an insight, caveat, or question.
Geisbüsch et al. (2008) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: